New Pill DOUBLES Pancreatic Cancer Survival — Stunning Results

Assorted pills on a reflective surface against a light background — MAJOR MEDICAL BREAKTHROUGH

A daily pill doubled pancreatic cancer survival from 6.7 to 13.2 months, slashing death risk by 60% in a trial that could rewrite treatment for this killer disease.

Story Highlights

Revolution Medicines’ daraxonrasib met all Phase 3 endpoints in second-line metastatic PDAC, outperforming chemotherapy with median OS of 13.2 vs. 6.7 months (HR 0.40, p < 0.0001).
RAS mutations drive 95% of PDAC cases; this oral RAS(ON) inhibitor targets them precisely, unlike broad chemo.
The company plans an FDA NDA submission using a National Priority Voucher for accelerated approval.
Parallel trials advance in first-line and adjuvant PDAC settings.
Full data expected at 2026 ASCO, positioning daraxonrasib as a potential practice-changer.

Phase 3 Trial Delivers Unprecedented Survival Gains

Revolution Medicines announced topline results from the RASolute 302 trial on April 13, 2026. Daraxonrasib, an oral once-daily RAS(ON) multi-selective inhibitor, treated patients with previously treated metastatic pancreatic ductal adenocarcinoma.

The global, randomized Phase 3 study compared daraxonrasib to standard chemotherapy. It met primary endpoint of overall survival and key secondary endpoints with high significance. Median OS reached 13.2 months versus 6.7 months, a hazard ratio of 0.40 and p-value under 0.0001.

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/nCo7loNB2R

— CNBC International (@CNBCi) April 13, 2026

Company Targets RAS Addiction in Deadly PDAC

Revolution Medicines, based in Redwood City, California, develops precision therapies for RAS-addicted cancers. Nearly all PDAC cases feature RAS mutations, making them ideal for daraxonrasib’s mechanism.

The drug blocks RAS(ON) proteins from interacting with downstream effectors, halting tumor growth. Unlike intravenous chemotherapy, patients take it as a pill. This approach aligns with conservative values favoring innovation that empowers patients over one-size-fits-all government-backed standards.

Prior milestones built momentum. On September 10, 2025, new clinical data emerged in metastatic PDAC. FDA granted Orphan Drug Designation October 27, 2025.

First patient dosed in adjuvant RASolute 304 trial December 18, 2025. These steps positioned RASolute 302 for success in second-line settings where chemo typically fails quickly.

CEO Goldsmith Drives Rapid Regulatory Push

Mark A. Goldsmith, M.D., Ph.D., CEO and Chairman, called results a dramatic improvement and potentially transformative advance. Revolution Medicines commits to swift global regulatory submissions, including FDA NDA via National Priority Voucher.

This voucher accelerates review for priority drugs, fitting common-sense urgency in unmet needs. No safety issues appeared in topline data. Detailed findings head to 2026 ASCO presentation.

Stakeholders include patients, investigators at global trial sites, and regulators. FDA holds approval power while oncology leaders like ASCO shape adoption. Investors watch stock impacts from milestones. Patients gain a targeted option doubling survival time over chemo’s grim baseline.

Precision Shift Reshapes Pancreatic Cancer Landscape

PDAC kills quickly; second-line chemo yields about 6.7 months median OS. Daraxonrasib’s 13.2 months marks unprecedented gain, validated across sources as groundbreaking. Past trials like CASSANDRA showed modest event-free survival bumps to 16 months neoadjuvant.

No prior RAS agent doubled OS in metastatic PDAC. This validates RAS(ON) inhibition, pressuring competitors and favoring precision over chemo in GI cancers.

📊 REVOLUTION MEDICINES' POTENTIAL BREAKTHROUGH PANCREATIC CANCER DRUG SUCCEEDS IN LATE-STAGE TRIAL

💡 Revolution Medicines' positive Phase 3 data for daraxonrasib validates RAS inhibition as a viable targeted approach in a cancer type long reliant on toxic chemo, unlocking a…

— Algofinix Inc (@algofinix) April 13, 2026

Short-term, accelerated approval could transform second-line care. Long-term, expansion to RASolute 303 first-line and RASolute 304 adjuvant settings redefines standards.

Patients with RAS-mutated tumors, 95% of cases, benefit most. Families extend precious time. Economically, targeted drugs carry high costs but deliver value through efficacy. Socially, hope pierces the intractable label on PDAC.